5000th patient treated with protons for eye tumours
From the patient's perspective at the treatment station: The proton beam is directed through the hole in the shield onto the tumour in the eye. The brass shield is adjusted to the individual tumour size and protects the surrounding tissue. © HZB/. S. Kodalle
The treatment centre for eye tumour therapy in Berlin-Wannsee © HZB/ S. Kodalle
For more than 25 years, Charité – Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have been jointly offering proton radiation therapy for eye tumours. The HZB operates a proton accelerator in Berlin-Wannsee for this purpose, while Charité provides medical care for the patients. The 5000th patient was treated at the beginning of August.
The treatment room and proton accelerator are specially adapted to the requirements for optimal and highly precise treatment of tumours inside the eye and are unique in this combination. The largest group of tumours in the eye is the rare and malignant uveal melanoma, which, as the name suggests, develops in the uvea of the eye.
Proton therapy is used as an effective method of fighting tumours, often as an alternative to removing the eye, with the aim of preserving the eye and its function as much as possible. The protons can be directed very precisely at the tumour, sparing the surrounding healthy tissue. Compared to other radiation methods, proton therapy causes less damage to the cornea, lens, retina and optic nerve in many cases.
8 August 2025 was a special day: it was the day on which the 5000th patient completed their eye tumour treatment. This makes the Berlin experts one of the world's leading centres: together, the two institutions (Charité and HZB) have treated 10 percent of all eye tumours treated with protons worldwide. The cooperation with Charité – Universitätsmedizin Berlin also opens up prospects for the further development of proton therapy in order to carry out even more precise and effective treatments in the future – for the benefit of patients.
- Magnetic field during catalyst synthesis triples ammonia yieldApplying an external magnetic field during the synthesis of CoFe₂O₄ electrocatalysts triples the ammonia yield during electrocatalytic conversion. The magnetic field alters the surface states of the spinel oxide thin films, making catalytically active sites more accessible. In the journal 'Advanced Functional Materials', a team led by Marcel Risch at HZB and Sanjay Mathur at University of Cologne demonstrates a scalable strategy for developing next-generation electrocatalysts for efficient and sustainable chemical production.
- Imaging Ellipsometry for Process Control of Thin-Film DevicesA German–Israeli research team led by Dr. Andreas Furchner has demonstrated how imaging ellipsometry enables non-destructive characterisation and quality control of microstructured MXene thin films during device fabrication. The authors used two complementary ellipsometry approaches for precise, multi-scale access to key material properties. The work positions imaging ellipsometry as a powerful platform for monitoring thin-film uniformity, device integrity, and functionality throughout processing, including critical lithographic steps. The study was published in Applied Physics Letters and selected as an Editor’s Pick.
- Cool vaccines in rural Kenya: solar solution has been awarded by UNIn May 2026, Tabitha Awuor Amollo is spending some weeks as a guest scientist at HZB, analysing perovskite thin films at BESSY II. The Kenyan physicist from Egerton University, Nairobi, was recently recognised for her achievements in research and teaching. For the development of a solar-powered refrigeration system for use in rural health centres, she has been awarded the 2026 Organization for Women in Science for the Developing World (OWSD)-Elsevier Foundation Award. An interview on exceptional projects and daily struggles of a scientist. Questions were asked by Antonia Rötger.